|
|
Die momentane Warrantsituation, wie ich sie sehe!!
Outstanding Share Data: As at November 8, 2016 , we had 11,670,775 common shares and 950,000 pre-funded warrants exercisable for common shares issued and outstanding, as well as 324,832 stock options outstanding. Warrants outstanding as at November 8, 2016 represented a total of 3,779,245 equivalent common shares (excluding common shares issuable upon exercise of the pre-funded warrants separately disclosed above).
29,675 October 2012 Investor Warrants 345.00 $ Ausübungskosten
25,996 July 2013 Warrants 185.00 $ Ausübungskosten
447,574 March 2015 Series A Warrants 3.41 $ Ausübungskosten
2,331,000 December 2015 Warrants 7.10 $ Ausübungskosten
http://secfilings.nasdaq.com/...20INC.&FormType=6-K&View=html
Mit der Nov 16 KE wurden 1,15 Mio Aktien, 0,95 Mio (vorfinanzierte) pre-funded warrants und 0,945 Mio Warrants ausgegeben.
http://secfilings.nasdaq.com/...INC.&FormType=SUPPL&View=html
Fasse das mal zusammen wie ich das sehe.
11,670,775 common shares und den schon bezahlten 950,000 pre-funded warrants
= 12,620,775 Aktien
Serie-A ausgeübt mit einigen ATM, Aktienanzahl ist nach Mac um 947,220 gestiegen.
= 13,567,995 Aktien die zusammen mit den pre-funded warrants ausstehen. Das sehe ich als momentane effektive Aktienzahl an.
Bleiben noch 29,675 October 2012 Investor Warrants, 25,996 July 2013 Warrants, 2,331,000 December 2015 Warrants, 0,945 Mio Nov 16 KE Warrants. ATM Anzahl ?
Die Anzahl der Warrants wird sich bei Ausübung in Aktien nicht übermäßig verändern. Mit Außnahme der Nov 16 Warrants ;-). Kann mich auch irren, sehe sie aber als Aktiendruckmaschine. Die haben aber durch die Ausübungssperre noch Zeit bis April 2017. Daher auch die Option die Warrants mit der 10$ Grenze zu annullieren. (Werde das später noch mal aufgreifen)
They are exercisable 6 months after their date of issuance ..........................
The warrants may at any time be exercised on a “net” or “cashless” basis in accordance with a customary formula. In addition, in the event the volume weighted average price of the Company’s common shares on the NASDAQ Capital Market attains or exceeds US$10.00 during 10 consecutive trading days, the Company will have the right to call for cancellation all or any portion of the warrants which are not exercised by holders within 10 trading days following receipt of a call notice from the Company. http://secfilings.nasdaq.com/...20INC.&FormType=6-K&View=html
auf der Zunge zergehen lassen!
That’s because Zoptrex is essentially the standard treatment paired with a compound that’s supposed to “aim” doxorubicin at the cancer cells more effectively.
Bisserl falsch. Richtig "in the cancer cells" :-)Bei PLD wird Dox an den Zellen abgegeben.
Bei Zopt in den Zellen! boreas, stimmt das? :-)
This is bad because with chemotherapies, more is not better. More is worse, actually, because the side effects get worse and worse.
Studien belegen das Gegenteil! Zoptrex ist Zielgerichtet! FDA hat auf eine Sicherheitsstudie verzichtet. Zopt hat schon bewiesen das es toleranter ist!
Here’s the clincher: 267 mg/m2 actually works out to be more doxorubicin than the standard dose of doxorubicin by itself. So much for aiming at the cancer cells more effectively.
267 mg/m2 of AEZS-108 is equimolar to 76.8 mg/m2 of doxorubicin.
Only 23% of the patients enrolled in the trial had had prior chemotherapy or hormonal therapy, so we would expect good efficacy from this first-time treatment
Second line hat schlechtere Ansprechraten!
50% of the patients in the trial received a different drug (carboplatin/paclitaxel) while undergoing treatment with Zoptrex
Patients received AEZS-108 as a 2-hour infusion on day 1 of a 21-day cycle. The treatment was continued for a maximum of 6 to 8 cycles
Only 23% of patients responded to the drug, even though it was the first time they’d had chemotherapy
On the contrary, 8 patients had received carboplatin/paclitaxel treatment before AEZS-108 therapy. Two of these had an objective response, and 3 achieved a stable disease on AEZS-108 treatment.
Wie gesagt, second line hat schlechtere Ansprechraten
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3921259/
http://journals.lww.com/ijgc/Abstract/2014/02000/...H_Agonist.13.aspx
http://phase3dd.com/category/failure-predicted/
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
25 | 17.117 | Aeterna nach dem Split | Heron | Hbit | 25.11.23 10:08 | |
9 | 13.769 | AEZS vs. KERX | Gropius | paioneer | 03.09.22 18:22 | |
19 | Wie geht's jetzt weiter mit Aeterna Zentaris? | Ebi52 | Bullish_Hope | 03.08.22 00:11 | ||
21 | 7.680 | Aeterna Zentaris Inc. | Heron | Heron | 30.09.21 23:37 | |
2 | 62 | AEterna Zentaris (AEZS)- Reboundkandidat?? | Vollzeittrader | marroni | 25.04.21 13:13 |